Skip to main content

Table 1 Overview of Patients included in the study

From: Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study

  Case-note review Interviews
Total number of Patients 62 13
 Male 45 10
 Female 17 3
Median age 66 (range 48–81)  
Disease
 Lung 51 11
 Prostate 4 0
 Bladder 4 1
 Head and Neck 2 0
 Squamous cell cancer of skin 1 1
Pembrolizumab 55 (11 trial) 10
Pembrolizumab +Docetaxel 2 (1 trial)  
Nivolumab 5 (5 trial)  
Atezolimumab 5 3
Median number of cycles 3 (range 1–32) 9 (range 2–30)